A potential microbial control for fireweed (Epilobium angustifolium)

Des plants infectés d'épi lobe à feuilles étroites (Epilobium angustifolium) ont été récoltés au Québec et les organismes isolés de ces plants ont été évalués comme agents potentiels de lutte biologique. Treize champignons pathogènes ont été isolés et trois d'entre eux (Colletotrichum dematium, Seimatosporium kriegerianum et Alternaria alternata) ont été virulents lors d'essais préliminaires de sélection. Le plus virulent de ceux-ci, C. dematium, a causé d'importantes lésions sur les feuilles et les tiges des plantes infectées et a été sélectionné pour une étude plus approfondie. La production d'inoculum a été optimale sur gélose à base d'extrait de malt modifié, et la virulence a été augmentée par l'enlèvement de la matrice des conidies à l'aide d'acide tannique et par l'addition d'extraits d'Aloe saponaria. La champignon a été pathogène pour l'épilobe à feuilles étroites et l'E. lanceolatum, alors que les autres espèces évaluées ont été résistantes ou immunisées. Les dimensions des conidies et des appressoria et le nombre restreint de plantes-hôtes supportent l'hypothèse que cet isolât pourrait être une forme-espèce non répertoriée. L'application d'une formulation de conidies âgées de 10 à 15 j, à une concentration de 109 conidies m-2 et après une période de rosée de 18 à 24 h, a causé la mortalité de 100% des rosettes d'épilobe à feuilles étroites âgées de 7 semaines dans les 48 h suivant l'application. La virulence a été réduite chez les plantes plus âgées. Dans l'essai au champ, la croissance des rosettes infectées a diminué de 33%. Ces résultats démontrent le potentiel de C. dematium comme agent de lutte biologique en sylviculture contre les plantules d'épilobe à feuilles étroites.Diseased fireweed (Epilobium angustifolium) plants were collected in Quebec and organisms isolated from these plants were evaluated as potential biocontrol agents. Thirteen pathogenic fungi were isolated and three of these (Colletotrichum dematium, Seimatosporium kriegerianum, and Alternaria alternata) were virulent in initial screening assays. C. dematium was selected for further study because it was the most virulent pathogen, causing large necrotic lesions on leaves and stems of infected plants. Inoculum production was optimized on modified malt extract agar and the virulence enhanced by suppression of the conidial matrix with tannic acid and the addition of extracts of Aloe saponaria. The fungus was pathogenic to fireweed and E. lanceolatum, while other test species were very resistant or immune. Measurements of conidial and appressorial dimensions and its restricted host range support the hypothesis that the isolate may be an unreported form-species. Application of formulated conidia consistently provided 100% mortality of 7-wk-old inoculated fireweed rosettes within 48 h using 109 conidia m-2, from 10- to 15-d-old inoculum, and a 18- to 24-h dew period. Virulence was diminished in older plants. In field trials, growth of inoculated rosettes was reduced by 33%. These results suggest that C. dematium is a promising candidate for further development as a control agent for seedling fireweed in silviculture

Toward mountains without permanent snow and ice

The cryosphere in mountain regions is rapidly declining, a trend that is expected to accelerate over the next several decades due to anthropogenic climate change. A cascade of effects will result, extending from mountains to lowlands with associated impacts on human livelihood, economy, and ecosystems. With rising air temperatures and increased radiative forcing, glaciers will become smaller and, in some cases, disappear, the area of frozen ground will diminish, the ratio of snow to rainfall will decrease, and the timing and magnitude of both maximum and minimum streamflow will change. These changes will affect erosion rates, sediment, and nutrient flux, and the biogeochemistry of rivers and proglacial lakes, all of which influence water quality, aquatic habitat, and biotic communities. Changes in the length of the growing season will allow low-elevation plants and animals to expand their ranges upward. Slope failures due to thawing alpine permafrost, and outburst floods from glacier- and moraine-dammed lakes will threaten downstream populations. Societies even well beyond the mountains depend on meltwater from glaciers and snow for drinking water supplies, irrigation, mining, hydropower, agriculture, and recreation. Here, we review and, where possible, quantify the impacts of anticipated climate change on the alpine cryosphere, hydrosphere, and biosphere, and consider the implications for adaptation to a future of mountains without permanent snow and ice

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research